The Oncology Institute, Inc.
TOI
$3.31
$0.082.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 18.19% | -4.10% | 22.17% | -6.05% | -7.66% |
| Total Depreciation and Amortization | 8.52% | 3.62% | 1.95% | -5.58% | -7.13% |
| Total Amortization of Deferred Charges | 0.44% | 1.41% | 0.38% | -0.83% | 0.38% |
| Total Other Non-Cash Items | -42.27% | 1,526.06% | -96.15% | -29.93% | -24.30% |
| Change in Net Operating Assets | 11.09% | 436.55% | -24.67% | -142.38% | 680.20% |
| Cash from Operations | 411.11% | 105.23% | 1.40% | -307.99% | 53.15% |
| Capital Expenditure | -536.57% | 122.02% | -199.34% | 29.15% | 7.42% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -50.00% | 0.02% | 58.16% | 46.36% |
| Cash from Investing | -116.87% | -42.77% | -6.25% | 66.75% | 50.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -217.66% | 11,111.11% | 99.11% | 69.17% | -227.79% |
| Issuance of Common Stock | -- | -100.00% | -97.26% | -35.40% | 769.23% |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 181.20% | 42.34% | -- | -- | 143.15% |
| Cash from Financing | 32.51% | 88.68% | -128.89% | 47.33% | -135.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -79.35% | 2,875.07% | -85.63% | -56.88% | 538.69% |